PIIND PI Industries Q3 FY26 results (Oct–Dec 2025) and concall
P I Industries reported a mixed Q3 FY26, with strong 50% YoY growth in its Pharma business and robust margins, but AgChem exports moderated and domestic demand remained subdued due to industry headwinds. The company maintains a debt-free balance sheet with significant cash, is progressing on new molecule commercialization, and anticipates a gradual recovery from Q4 FY26, with growth momentum building into FY27.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 27.6%, net profit down 16.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 2,221 | 1,901 | 1,787 | 1,900 | 1,872 −16% | 1,376 −28% |
| EBITDA | 628 | 512 | 456 | 519 | 541 −14% | 302 −41% |
| Net profit | 508 | 373 | 330 | 400 | 409 −19% | 311 −17% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
